Sponsor
- Home
- Your Messages
-
Smartest Doc
Daily Quiz CompetitionTest your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
New! PHYSICIAN REVIEW
Thousands of questions to assess your knowledge and aid exam prep!
- Physician Jobs (1019)
- More
- Other Specialty
Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations
Journal of Clinical Pharmacy and Therapeutics, 06/01/2012
Aoki T et al. – The successful treatment of ITP refractory to eltrombopag with romiplostim strongly suggests that the absence of cross–resistance between these two approved TPO receptor agonists and possible differences in mechanism of action. Further study of the mechanisms of action of TPO receptor agonists is called for along with further exploration of the potential of romiplostim in refractory ITP.
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor